Literature DB >> 7033353

Ulcer healing and relapse rates after initial treatment with cimetidine or sucralfate.

I N Marks, W Lucke, J P Wright, A H Girdwood.   

Abstract

Ulcer healing and relapse rates after treatment with cimetidine and sucralfate in 112 subjects with endoscopically proven gastric and duodenal ulcers were compared in a randomized trial. Four grams of sucralfate were administered in four divided doses each day; 200 mg cimetidine was administered three times during the day with the fourth dose of 400 mg given at night. The subjects were divided into four treatment groups: (1) subjects with duodenal ulcers treated with sucralfate; (2) subjects with duodenal ulcers treated with cimetidine; (3) subjects with gastric ulcers treated with sucralfate; and (4) subjects with gastric ulcers treated with cimetidine. Endoscopy was repeated at 6 weeks after treatment was initiated; subjects with unhealed ulcers at 6 weeks were reendoscoped at 12 weeks. Eighty-three percent of duodenal ulcers in subjects treated with sucralfate healed at 6 weeks, the rest by week 12. Cimetidine-treated subjects with duodenal ulcer had healing rates of 71 and 86% at 6 and 12 weeks. Cimetidine-treated subjects with gastric ulcers showed healing rates of 75 and 89% at 6 and 12 weeks, respectively. In the gastric ulcer group, 63% of sucralfate-treated subjects were healed at 6 weeks, and 78% were healed by 12 weeks, respectively. Eighty-six of the subjects were followed for 1 year or until endoscopy showed relapse. Subjects treated with cimetidine on a short-term basis relapsed earlier than those were treated with sucralfate at 12 weeks, but at 1 year, the relapse rates were about 70% for both groups.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7033353

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

1.  The refractory ulcer.

Authors:  D W Piper
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

2.  Deformity of duodenal bulb, gastric metaplasia of duodenal regenerating mucosa and recurrence of duodenal ulcer: a correlated study.

Authors:  Chun-Chao Chang; Shiann Pan; Gi-Shih Lien; Cheng-Hsiung Liao; Sheng-Hsuan Chen; Yeong-Shan Cheng
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

3.  Comparison of relapse rates and of mucosal abnormalities after healing of duodenal ulceration and after one year's maintenance with cimetidine or sucralfate: a light and electron microscopy study.

Authors:  F I Tovey; E M Husband; Y C Yiu; L Baker; G McPhail; M R Lewin; A P Jayaraj; C G Clark
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

4.  Utilization of a human intestinal epithelial cell culture system (Caco-2) for evaluating cytoprotective agents.

Authors:  A S Tang; P J Chikhale; P K Shah; R T Borchardt
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

Review 5.  Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

6.  Deduction of duodenal ulcer recurrence by healing with cimetidine plus sulpiride.

Authors:  M Tatsuta; H Iishi; S Okuda
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

7.  Rebamipide, novel prostaglandin-inducer accelerates healing and reduces relapse of acetic acid-induced rat gastric ulcer. Comparison with cimetidine.

Authors:  T Arakawa; T Watanabe; T Fukuda; K Yamasaki; K Kobayashi
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

8.  Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man.

Authors:  S J Konturek; N Kwiecień; W Obtułowicz; B Kopp; J Oleksy
Journal:  Gut       Date:  1986-12       Impact factor: 23.059

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.